Cargando…

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia

INTRODUCTION: Guidelines for the use of cerebrospinal fluid (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) establish that each laboratory must use internally qualified cutoff values. We determined the concentrations of biomarkers that discriminate cases from controls and combinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forlenza, Orestes V., Radanovic, Marcia, Talib, Leda L., Aprahamian, Ivan, Diniz, Breno S., Zetterberg, Henrik, Gattaz, Wagner F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	CSF Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879480/ https://www.ncbi.nlm.nih.gov/pubmed/27239524 http://dx.doi.org/10.1016/j.dadm.2015.09.003

Ejemplares similares

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Decision tree-based classification as a support to diagnosis in the Alzheimer’s disease continuum using cerebrospinal fluid biomarkers: insights from automated analysis
por: Costa, Alana, et al.
Publicado: (2022)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Diagnosis and biomarkers of predementia in Alzheimer's disease
por: Forlenza, Orestes V, et al.
Publicado: (2010)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Correlation between CSF biomarkers of Alzheimer’s disease and global cognition in a psychogeriatric clinic cohort
por: Radanovic, Márcia, et al.
Publicado: (2019)

Increased CSF levels of total Tau in patients with subcortical cerebrovascular pathology and cognitive impairment
por: Radanovic, Márcia, et al.
Publicado: (2017)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Complications of external cerebrospinal fluid drainage in aneurysmal subarachnoid haemorrhage
por: Arts, Sebastian, et al.
Publicado: (2021)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
por: Pais, Marcos, et al.
Publicado: (2020)

Cerebrospinal fluid dynamics in idiopathic intracranial hypertension: a literature review and validation of contemporary findings
por: Kaipainen, Aku L, et al.
Publicado: (2021)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

Electroconvulsive therapy for treating patients with agitation and related behavioral disorders due to dementia: a systematic review
por: Stella, Florindo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_45jh3nlrek1t8st46vneukq499